

## INVESTOR WEBINAR PRESENTATION

Genetic Signatures Limited (ASX: GSS, “Genetic Signatures” or the “Company”) is pleased to announce its participation in the ShareCafe Small Cap “Hidden Gems” Webinar, to be held Friday 18<sup>th</sup> of February 2022 from 12:30pm AEDT / 9:30am AWST.

Chief Executive Officer Dr. John Melki will provide an overview of the development and commercialisation of the Company’s proprietary platform technology, **3base®**. The **3base®** platform provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens with a high degree of specificity in rapid time.

This webinar is able to be viewed live via Zoom and will provide viewers the opportunity to hear from, and engage with, a range of ASX-listed leading micro/mid cap companies.

To access further details of the event and to register at no cost, please copy and paste the following link into your internet browser:

[https://us02web.zoom.us/webinar/register/3216444590728/WN\\_xXhnUtOFRmKy99-5ik47TA](https://us02web.zoom.us/webinar/register/3216444590728/WN_xXhnUtOFRmKy99-5ik47TA)

A recorded copy of the webinar will be made available following the event.

***Announcement authorised by Genetic Signatures’ Board of Directors***

For further information, see our website ([www.geneticsignatures.com](http://www.geneticsignatures.com)) or contact us as below:

**Dr John Melki**

**Chief Executive Officer**

[john.melki@geneticsignatures.com](mailto:john.melki@geneticsignatures.com)

T: +61 (0)2 9870 7580

**Peter Manley**

**Chief Financial Officer**

[peter.manley@geneticsignatures.com](mailto:peter.manley@geneticsignatures.com)

**About Genetic Signatures Limited:** Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base®**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures’ proprietary MDx **3base®** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospital and pathology laboratories undertaking infectious disease screening.